IOVANCE CMO reports RSU vesting and tax withholding

IOVANCE BIOTHERAPEUTICS, INC.

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported routine equity compensation activity involving restricted stock units (RSUs). On the transaction date, 7,813 RSUs vested, each converting into one share of common stock. These shares were acquired through an option-style derivative exercise at a stated price of $0.00 per share.

To cover mandatory tax withholding on the vesting, 3,976 common shares were withheld by the company, which the filing clarifies was not an open market sale. After these transactions, the officer directly held 140,111 shares of common stock. The filing also notes 54,691 RSUs remaining from a March 5, 2025 grant, which will vest in equal quarterly installments, providing additional potential future share deliveries as they vest.

Insider Trade Summary

7,813 shares exercised/converted

Exercise 3 txns

Insider GRAF FINCKENSTEIN FRIEDRICH

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	7,813	$0.00	$0.00
Exercise	Common Stock	7,813	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	3,976	$4.23	$17K

Holdings After Transaction: Restricted Stock Units — 54,691 contracts (Direct); Common Stock — 140,111 shares (Direct)

Footnotes (6)

1. F1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
2. F2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
3. F3. Represents the common stock remaining after deducting the common stock withheld for taxes.
4. F4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
5. F5. The remaining RSUs will vest in equal quarterly installments.
6. F6. Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.

Key Figures

RSUs vested: 7,813 units Shares withheld for taxes: 3,976 shares Common shares held after transaction: 140,111 shares +2 more

5 metrics

RSUs vested 7,813 units RSUs converted into common stock on transaction date

Shares withheld for taxes 3,976 shares Mandatory tax withholding on RSU vesting

Common shares held after transaction 140,111 shares Direct ownership following RSU vesting and tax withholding

Remaining RSUs from March 5, 2025 grant 54,691 units Scheduled to vest in equal quarterly installments

Exercise price per share $0.00 per share Stated price for RSU-related derivative exercise into common stock

Key Terms

Restricted Stock Units, tax withholding, derivative security, vest

4 terms

Restricted Stock Units financial

"The filing reports activity in "Restricted Stock Units" that convert into common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding financial

"Shares were withheld by the issuer to satisfy mandatory tax withholding requirements upon vesting."

Tax withholding is the practice of taking a portion of a payment—such as wages, dividends, or sale proceeds—before it reaches the recipient and sending that portion to the tax authority as an advance on the recipient’s eventual tax bill. For investors it matters because withholding reduces immediate cash received and affects after‑tax returns, estimated tax payments, and whether you may owe more or receive a refund when taxes are finally calculated, like having a small automatic savings set aside for your tax bill.

derivative security financial

"The transaction code description notes an exercise or conversion of a derivative security."

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vest financial

"Footnotes state the RSUs vested on the transaction date and remaining RSUs will vest quarterly."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock activity did IOVANCE (IOVA) disclose for its Chief Medical Officer?

IOVANCE’s Chief Medical Officer reported RSU vesting that delivered 7,813 common shares and a related tax-withholding share disposition. The activity reflects routine equity compensation rather than open market buying or selling, according to the detailed transaction codes and accompanying footnotes.

How many IOVANCE (IOVA) shares were withheld for taxes in this Form 4?

The filing shows 3,976 IOVANCE common shares were withheld to satisfy mandatory tax obligations upon RSU vesting. Footnotes emphasize this was not an open market sale but an internal withholding mechanism tied directly to the equity award’s vesting event.

How many IOVANCE (IOVA) shares does the insider hold after these transactions?

Following the reported RSU vesting and tax withholding, the Chief Medical Officer directly holds 140,111 shares of IOVANCE common stock. This figure reflects the remaining shares after deducting the 3,976 shares withheld to cover taxes on the newly vested restricted stock units.

What are the details of the vested and remaining RSUs for IOVANCE (IOVA)?

On the transaction date, 7,813 RSUs vested, each representing one share of common stock. The filing also notes 54,691 RSUs from a March 5, 2025 grant remain outstanding, scheduled to vest in equal quarterly installments over future periods until fully delivered.

Did the IOVANCE (IOVA) insider sell shares in the open market in this filing?

No open market sale occurred. The filing explains that 3,976 shares were withheld by IOVANCE solely to satisfy mandatory tax withholding on RSU vesting. This disposition is classified as tax-withholding, not as a discretionary market sale of common stock.

How does this IOVANCE (IOVA) Form 4 classify the insider transactions?

The Form 4 classifies one transaction as an RSU-derived exercise acquiring 7,813 common shares and another as a tax-withholding disposition of 3,976 shares. Both are described as derivative-related and compensation-driven events rather than open market purchases or sales of the company’s stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAF FINCKENSTEIN FRIEDRICH

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	06/05/2026		M		7,813	A	$0	144,087	D
Common Stock(2)	06/05/2026		F		3,976	D	$4.23	140,111(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(4)	06/05/2026		M			7,813	(5)	(5)	Common stock	7,813	$0.00	54,691(6)	D

Explanation of Responses:

1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.

2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.

3. Represents the common stock remaining after deducting the common stock withheld for taxes.

4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

5. The remaining RSUs will vest in equal quarterly installments.

6. Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.

	/s/ Friedrich Graf Finckenstein	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)